Dr. Jennifer Altomonte Smarter Cancer Therapies with Fusix Biotech Stories in Life Sciences

Most cancer therapies target tumors from a single angle. When tumors adapt and escape, treatment stops working. In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Dr. Jennifer Altomonte, molecular biologist and founder of Fusix Biotech, to explore a different approach built on engineered viruses that attack tumors from multiple directions at once.Dr. Altomonte shares her journey from New York to Munich, decades in virus engineering, and the moment she realized her lab had developed something with the potential to change how cancer is treated. Fusix Biotech's therapy kills tumor cells directly, delivers immune-boosting genes, and activates the patient's immune system to continue fighting long after the drug is gone.In this episode of Stories in Life Sciences, we cover:How engineered oncolytic viruses attack tumors from multiple angles to overcome resistanceThe science behind Fusix Biotech's approach to cancer therapyWhy hitting tumors with multiple mechanisms reduces the risk of immune escapeThe role of AI in identifying biomarkers and guiding cancer therapy developmentDr. Altomonte's journey from academic virus engineering to biotech entrepreneurshipThe transition from academia to founding a biotech company and what it requiresBuilding conviction and networks in a field where failure is commonWho this is for: oncology researchers, biotech founders, clinicians, and investors in cancer therapy, immunotherapy, and life sciences innovation who want to understand where engineered virus platforms are headed.Guest: Dr. Jennifer AltomonteManaging Director and CSO, Fusix Biotech www.fusixbiotech.de https://www.linkedin.com/company/fusix-biotechHost:Christopher Wilson, Founder, MedAxis AIwww.medaxisai.orghttps://www.linkedin.com/in/christopher-wilson-medaxisai https://www.linkedin.com/company/medaxisaiFollow Stories in Life Sciences on Spotify, Apple Podcasts, and YouTube for new episodes.